BG102710A - Метод за контролиране на хемотерапия на нiv-положителни пациенти, основан на фенотипна чувствителност към ле- карства на човешки нiv-щамове - Google Patents
Метод за контролиране на хемотерапия на нiv-положителни пациенти, основан на фенотипна чувствителност към ле- карства на човешки нiv-щамовеInfo
- Publication number
- BG102710A BG102710A BG102710A BG10271098A BG102710A BG 102710 A BG102710 A BG 102710A BG 102710 A BG102710 A BG 102710A BG 10271098 A BG10271098 A BG 10271098A BG 102710 A BG102710 A BG 102710A
- Authority
- BG
- Bulgaria
- Prior art keywords
- hiv
- chimerical
- inhibitor
- data
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Методът осигурява фенотипна информация за индивидуални, заразени с НIV пациенти в широки мащаби икономично и бързо. Той е приложим към всички наличнив момента химиотерапевтични режими и може да бъдееднакво приложим и при бъдещи такива режими. Методът включва трансфекция на клетъчна линия, податлива на инфекция с НIV, с последователност, за предпочитане тази, която кодира RT и протеаза от pol гена на НIV, получен от пациент, и с HIV-ДНК конструкт, от който последователността е делетирана. Трансфектираните клетки се култивират, така че да се създаде резерв от химерични вируси, след което се оценява тяхната фенотипна чувствителност към инхибитор на ензима, кодиран от pol гена на НIV, като в допълнение се определя стойност. След това се конструира набор от данни, състоящ се от стойността зачувствителност на химеричния вирус и съответната стойност за химеричния див тип щам НIV, повтаря се оценката на чувствителността за най-малко още два инхибитора и по такъв начин се конструират като цяло най-малко три такива набора от данни. Наборите от данни се представят в двудименсиална или тридименсиална графична форма, така че разликите между чувствителностите на химеричните и дивите типове за всеки един набор от данни да осигуряват визуално измерване на устойчивостта на химеричния резерв на третиране с въпросния инхибитор. След това се подбира оптималният инхибитор(и) въз основа на графичното представяне на измерената устойчивост.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96200175 | 1996-01-26 | ||
PCT/IB1997/000071 WO1997027480A1 (en) | 1996-01-26 | 1997-01-24 | Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains |
Publications (1)
Publication Number | Publication Date |
---|---|
BG102710A true BG102710A (bg) | 1999-03-31 |
Family
ID=8223611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG102710A BG102710A (bg) | 1996-01-26 | 1998-08-20 | Метод за контролиране на хемотерапия на нiv-положителни пациенти, основан на фенотипна чувствителност към ле- карства на човешки нiv-щамове |
Country Status (21)
Country | Link |
---|---|
US (3) | US6221578B1 (bg) |
EP (1) | EP0877937B1 (bg) |
KR (1) | KR100495690B1 (bg) |
CN (2) | CN1209875A (bg) |
AT (1) | ATE217971T1 (bg) |
AU (1) | AU717755B2 (bg) |
BG (1) | BG102710A (bg) |
BR (1) | BR9707204A (bg) |
CZ (1) | CZ292899B6 (bg) |
DE (1) | DE69712731T2 (bg) |
ES (1) | ES2177922T3 (bg) |
HU (1) | HU226203B1 (bg) |
IL (1) | IL125442A (bg) |
IS (1) | IS4799A (bg) |
NO (1) | NO321329B1 (bg) |
NZ (1) | NZ325912A (bg) |
PL (1) | PL186473B1 (bg) |
SK (1) | SK283878B6 (bg) |
TR (1) | TR199801443T2 (bg) |
WO (1) | WO1997027480A1 (bg) |
ZA (1) | ZA97669B (bg) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100336699B1 (ko) | 1992-08-25 | 2002-05-13 | 윌리암스 로저 에이 | 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드 |
US20030220276A1 (en) * | 1995-05-16 | 2003-11-27 | Opendra Narayan | HIV vaccine and method of use |
US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US20070010471A1 (en) * | 1997-05-02 | 2007-01-11 | Opendra Narayan | HIV DNA vaccine |
AU8897698A (en) * | 1997-07-30 | 1999-02-22 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
NZ508834A (en) * | 1998-05-26 | 2004-06-25 | Virologic Inc | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy |
ATE302287T1 (de) | 1999-05-28 | 2005-09-15 | Virco Nv | Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz |
US6800437B1 (en) | 1999-08-06 | 2004-10-05 | Tibotec Bvba | Method of monitoring a biological system by labeling with an apo metal binding protein |
EP1109019A1 (en) * | 1999-12-15 | 2001-06-20 | BioStrands S.r.l. | Method to evaluate the sensitivity of HIV variants to drugs able to inhibit the HIV protease |
WO2001057245A2 (en) * | 2000-02-04 | 2001-08-09 | K.U.Leuven Research & Development | Hiv-1 resistance assay |
GB0009374D0 (en) * | 2000-04-14 | 2000-05-31 | Glaxo Group Ltd | Phenotyping assay and reagents therefor |
ES2373488T3 (es) * | 2000-04-18 | 2012-02-06 | Virco Bvba | Métodos para medir la resistencia a los fármacos frente a hcv. |
US6800463B1 (en) | 2000-04-20 | 2004-10-05 | Virco Bvba | Method for mutation detection in HIV-1 using pol sequencing |
EP1276909B1 (en) * | 2000-04-20 | 2013-11-13 | Janssen Diagnostics BVBA | Method for mutation detection in hiv using pol sequencing |
US6582901B2 (en) * | 2000-04-26 | 2003-06-24 | Bruce K. Patterson | Cell specific anti-viral drug susceptibility test using tagged permissive target cells |
US7058616B1 (en) | 2000-06-08 | 2006-06-06 | Virco Bvba | Method and system for predicting resistance of a disease to a therapeutic agent using a neural network |
AU2001266863A1 (en) * | 2000-06-12 | 2001-12-24 | Virologic, Inc. | Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
US6582920B2 (en) | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
AU2002212344B2 (en) * | 2000-10-20 | 2007-05-17 | Virco Bvba | Establishment of biological cut-off values for predicting resistance to therapy |
EP1356082A2 (en) | 2000-10-20 | 2003-10-29 | Virco Bvba | Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
US7306901B2 (en) | 2001-08-08 | 2007-12-11 | Tibotec Pharmaceuticals, Ltd. | Methods and means for assessing HIV envelope inhibitor therapy |
US6958211B2 (en) * | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
DE60225587T2 (de) | 2001-11-08 | 2009-04-02 | Aaron Diamond Aids Research Center | Protease assay zur kontrolle medikamentöser therapie |
CA2490862A1 (en) * | 2002-07-01 | 2004-01-08 | Tibotec Pharmaceuticals Ltd. | Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance |
AU2003251732B2 (en) | 2002-07-01 | 2008-09-18 | Tibotec Pharmaceuticals Ltd. | New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance |
WO2005086061A2 (en) * | 2004-03-02 | 2005-09-15 | Virco Bvba | Estimation of clinical cut-offs |
CN101365808B (zh) | 2005-12-07 | 2012-04-25 | 泰博特克药品有限公司 | 用于评估hiv病毒适应度的方法、质粒载体和引物 |
AU2007239535B2 (en) * | 2006-04-14 | 2012-12-20 | Tibotec Pharmaceuticals Ltd. | Methods and means for assessing HIV gag/protease inhibitor therapy |
CA2688278A1 (en) | 2007-05-25 | 2008-12-04 | Tibotec Pharmaceuticals | New mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance |
CA2739532A1 (en) * | 2008-10-06 | 2010-04-15 | Virco Bvba | Method for determining drug resistance mutations in any of the non-structural protein regions ns3 to ns5b of hepatitis c virus (hcv) for genotypes 1 to 6 |
CA2760781A1 (en) * | 2009-05-12 | 2010-11-18 | Virco Bvba | Hiv-1-c resistance monitoring |
CN107085093B (zh) * | 2017-03-24 | 2019-06-21 | 西藏诺迪康药业股份有限公司 | 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3875396A (en) * | 1973-11-12 | 1975-04-01 | Illuminite Corp | Illuminated clipboard |
US4675147A (en) * | 1983-04-06 | 1987-06-23 | Westinghouse Electic Corp. | Generating an integrated graphic display of the safety status of a complex process plant |
US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
IL94482A (en) | 1989-05-25 | 2003-09-17 | Univ Duke | Transdominant repressor mutant of retroviral protein, dna encoding the protein and process for their preparation and use thereof |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
JPH05148202A (ja) * | 1991-04-10 | 1993-06-15 | Tsumura & Co | 新規な化合物およびその医薬としての用途 |
AU4248593A (en) | 1992-05-14 | 1993-12-13 | Mark Holodniy | Polymerase chain reaction assays for monitoring antiviral therapy |
US5733720A (en) | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
ATE162225T1 (de) | 1992-07-06 | 1998-01-15 | Harvard College | Verfahren und diagnostische kits zur bestimmung der toxizität einer verbindung unter verwendung von an bakterielle stresspromotoren fusionierten reportergenen |
US5344846A (en) | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
US5591579A (en) | 1993-12-21 | 1997-01-07 | Washington University | Indicator cell line for detecting RNA viruses and method therefor |
US6063562A (en) | 1994-09-16 | 2000-05-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst |
US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
WO1997012220A2 (en) | 1995-09-15 | 1997-04-03 | Samir Chachoua | Method for the identification and therapeutic use of disease-associated organisms, elements and forces |
US5885806A (en) * | 1995-11-28 | 1999-03-23 | The Johns Hopkins University School Of Medicine | Methods to prepare conditionally replicating viral vectors |
ATE447621T1 (de) | 1996-01-29 | 2009-11-15 | Monogram Biosciences Inc | Verfahren zur bestimmung antiviraler wirkstoff suszeptibilität und resistenz sowie antivirales wirkstoff-screening |
US5837464A (en) | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US5945276A (en) | 1996-04-10 | 1999-08-31 | Signal Pharmaceuticals, Inc. | Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression |
US5939253A (en) | 1996-04-26 | 1999-08-17 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting viral infection |
DK1435519T3 (da) | 1997-04-07 | 2007-06-11 | Fisher Bioimage Aps | Fremgangsmåde til screening af substanser for effekt på cAMP-niveauer baseret på intracellulær translokation af PKA |
US6365347B1 (en) | 1997-04-11 | 2002-04-02 | The Regents Of The University Of California | Method for identifying disruptors of biological pathways using genetic selection |
WO1998059074A1 (en) | 1997-06-23 | 1998-12-30 | Emory University | Human immunodeficiency viruses causing aids in a nonhuman primate |
US5976813A (en) | 1997-12-12 | 1999-11-02 | Abbott Laboratories | Continuous format high throughput screening |
-
1997
- 1997-01-24 NZ NZ325912A patent/NZ325912A/xx not_active IP Right Cessation
- 1997-01-24 TR TR1998/01443T patent/TR199801443T2/xx unknown
- 1997-01-24 IL IL12544297A patent/IL125442A/en not_active IP Right Cessation
- 1997-01-24 KR KR10-1998-0705747A patent/KR100495690B1/ko not_active IP Right Cessation
- 1997-01-24 WO PCT/IB1997/000071 patent/WO1997027480A1/en not_active Application Discontinuation
- 1997-01-24 BR BR9707204-4A patent/BR9707204A/pt not_active Application Discontinuation
- 1997-01-24 CN CN97191904A patent/CN1209875A/zh active Pending
- 1997-01-24 SK SK1002-98A patent/SK283878B6/sk not_active IP Right Cessation
- 1997-01-24 ES ES97900712T patent/ES2177922T3/es not_active Expired - Lifetime
- 1997-01-24 PL PL97328069A patent/PL186473B1/pl not_active IP Right Cessation
- 1997-01-24 AT AT97900712T patent/ATE217971T1/de active
- 1997-01-24 CZ CZ19982335A patent/CZ292899B6/cs not_active IP Right Cessation
- 1997-01-24 AU AU13168/97A patent/AU717755B2/en not_active Ceased
- 1997-01-24 DE DE69712731T patent/DE69712731T2/de not_active Expired - Lifetime
- 1997-01-24 HU HU9902618A patent/HU226203B1/hu not_active IP Right Cessation
- 1997-01-24 CN CNA2006101685069A patent/CN1991365A/zh active Pending
- 1997-01-24 EP EP97900712A patent/EP0877937B1/en not_active Expired - Lifetime
- 1997-01-24 US US09/117,217 patent/US6221578B1/en not_active Expired - Lifetime
- 1997-12-27 ZA ZA9700669A patent/ZA97669B/xx unknown
-
1998
- 1998-07-16 NO NO19983300A patent/NO321329B1/no not_active IP Right Cessation
- 1998-07-20 IS IS4799A patent/IS4799A/is unknown
- 1998-08-20 BG BG102710A patent/BG102710A/bg unknown
-
2000
- 2000-12-14 US US09/735,487 patent/US6528251B2/en not_active Expired - Fee Related
-
2003
- 2003-01-15 US US10/342,188 patent/US20030152917A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG102710A (bg) | Метод за контролиране на хемотерапия на нiv-положителни пациенти, основан на фенотипна чувствителност към ле- карства на човешки нiv-щамове | |
Ten Haaft et al. | A pathogenic threshold of virus load defined in simian immunodeficiency virus-or simian-human immunodeficiency virus-infected macaques | |
Kim et al. | Conservation of a packaging signal and the viral genome RNA packaging mechanism in alphavirus evolution | |
Trobridge et al. | Foamy virus vector integration sites in normal human cells | |
Lobert et al. | A coding RNA sequence acts as a replication signal in cardioviruses | |
Berkhout et al. | Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains | |
Sawai et al. | Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef | |
Kaiser et al. | Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes | |
Corbeau et al. | Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line | |
Ince et al. | Evolution of the HIV-1 env gene in the Rag2−/− γC−/− humanized mouse model | |
Wentz et al. | A naturally arising mutation of a potential silencer of exon splicing in human immunodeficiency virus type 1 induces dominant aberrant splicing and arrests virus production | |
Arya et al. | Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: expression and potential for helper virus-free packaging | |
Wang et al. | Preclinical characterization of an anti-tat ribozyme for therapeutic application | |
Protić et al. | Enhancement of DNA repair capacity of mammalian cells by carcinogen treatment | |
Carl et al. | Partial “repair” of defective NEF genes in a long-term nonprogressor with human immunodeficiency virus type 1 infection | |
Edmonson et al. | Evolution of a simian immunodeficiency virus pathogen | |
Shen et al. | Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence | |
Markine-Goriaynoff et al. | The core 2 β-1, 6-N-acetylglucosaminyltransferase-mucin encoded by bovine herpesvirus 4 was acquired from an ancestor of the African buffalo | |
Sinclair et al. | The nef gene products of both simian and human immunodeficiency viruses enhance virus infectivity and are functionally interchangeable | |
Wang et al. | Characterization of equine infectious anemia virus long terminal repeat quasispecies in vitro and in vivo | |
Cheng et al. | Human immunodeficiency virus type 1 genome activation induced by human T-cell leukemia virus type 1 Tax protein is through cooperation of NF-κB and Tat | |
Beer et al. | Vaccine effect using a live attenuated nef-deficient simian immunodeficiency virus of African green monkeys in the absence of detectable vaccine virus replication in vivo | |
Renjifo et al. | cis-acting elements in the U3 region of a simian immunodeficiency virus | |
Chen et al. | Methods taught in dental schools for determining the posterior palatal seal region. | |
Linder et al. | An anticodon nuclease gene inserted into a hsd region encoding a type I DNA restriction system. |